Agarwal Anurag, Heron Dwight E, Sumkin Jules, Falk Jeff
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA.
J Surg Oncol. 2005 Oct 1;92(1):4-8. doi: 10.1002/jso.20282.
Sentinel lymph node mapping as a constitutive component in the staging process for invasive breast cancer continues to gain acceptance. We have identified two patients with recurrent invasive breast cancer in whom contralateral sentinel lymph node uptake and metastases, respectively, were detected. Such findings have not been previously reported in our review of the medical literature between 1966 and October 2004.
Sentinel lymph node mapping was performed on two patients with recurrent invasive breast cancer at our institution. At the time of their index diagnosis, both had received breast conserving surgery and an axillary lymph node dissection with post-operative radiotherapy (RT). All lymph nodes and margins of resection were without tumor. Both patients remained with no evidence of disease for years until routine serial screening mammography was interpreted as suspicious. Each underwent a stereotactic biopsy of the ipsilateral breast corresponding to the mammographic abnormality. Pathology confirmed invasive ductal carcinoma. Both patients refused the recommended salvage mastectomy.
During a second attempt at breast conservation, sentinel lymph node mapping--which is typically contraindicated for patients with prior axillary surgery--revealed contralateral axillary uptake for both patients. The respective contralateral sentinel node was excised with pathology revealing no tumor in one case, and a microscopic focus of metastatic carcinoma in the second case.
Some patients may benefit from sentinel lymph node mapping prior to salvage mastectomy. Identifying uptake in a contralateral sentinel lymph node may change the multi-disciplinary management of recurrent invasive breast cancer to include a contralateral axillary dissection, chemotherapy, and/or RT to the contralateral axilla.
前哨淋巴结定位作为浸润性乳腺癌分期过程的一个组成部分,其认可度不断提高。我们发现了两名复发性浸润性乳腺癌患者,分别检测到对侧前哨淋巴结摄取及转移情况。在我们对1966年至2004年10月间医学文献的回顾中,此前尚未有此类发现的报道。
我们机构对两名复发性浸润性乳腺癌患者进行了前哨淋巴结定位。在初次诊断时,两人均接受了保乳手术及腋窝淋巴结清扫,并术后放疗(RT)。所有淋巴结及手术切缘均无肿瘤。两名患者多年来均无疾病证据,直到常规系列筛查乳腺钼靶检查结果被解读为可疑。两人均对与乳腺钼靶异常对应的同侧乳房进行了立体定向活检。病理证实为浸润性导管癌。两名患者均拒绝了推荐的挽救性乳房切除术。
在第二次保乳尝试过程中,前哨淋巴结定位——这通常对既往有腋窝手术史的患者是禁忌的——显示两名患者均有对侧腋窝摄取。分别切除了对侧前哨淋巴结,病理显示一例无肿瘤,另一例有微小转移癌灶。
一些患者在挽救性乳房切除术前可能从前哨淋巴结定位中获益。识别对侧前哨淋巴结摄取情况可能会改变复发性浸润性乳腺癌的多学科管理,包括进行对侧腋窝清扫、化疗和/或对对侧腋窝进行放疗。